TCTing Chen

Ting Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ting Chen has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Xudong Tang

    Institute of Digestive Diseases, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China

    5 shared publications
  • Jiaqi Zhang

    Institute of Digestive Diseases, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China

    3 shared publications
  • Meiling She

    Institute of Digestive Diseases, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China

    3 shared publications
  • Xuan Li

    Institute of Digestive Diseases, China Academy of Chinese Medical Sciences Xiyuan Hospital, Beijing, China

    3 shared publications
  • Yibing Tian

    Department of Chinese Medicine, Eye Hospital, China Academy of Chinese Medical Sciences

    3 shared publications
  • Zhongyu Li

    Department of Chinese Medicine, Eye Hospital, China Academy of Chinese Medical Sciences

    3 shared publications

Latest Publications

  • Open Access

    Multi-omics analysis provides clues in understanding diarrhea-predominant irritable bowel syndrome with concomitant nonerosive reflux disease

    by Yuedan Wang, Meiling She, Lihui Fang, Jiaqi Zhang, Ting Chen, Beihua Zhang, Xudong Tang

  • Open Access

    From inflammation to carcinogenesis: MiRNA regulates epithelial-mesenchymal transition to facilitate malignant progression of gastric precancerous lesions

    by Yibing Tian, Tai Zhang, Bochao Yuan, Zhongyu Li, Ting Chen, Yandong Wen

    The process of chronic gastritis transforming into gastric cancer (GC) follows the classic Correa cascade, with persistent inflammation driving the stepwise transition from normal gastric mucosa through superficial gastritis, atrophic gastritis, intestinal metaplasia, dysplasia, and ultimately carcinoma. Among these stages, intestinal metaplasia and dysplasia occurring on an atrophic mucosal background are widely regarded as the most common gastric precancerous lesions (GPL) because of their pronounced carcinogenic risk. Chronic inflammation can induce epithelial–mesenchymal transition (EMT), thereby accelerating gastric malignant progression. In the GPL stage, the inflammatory gastric microenvironment commonly induces partial EMT (pEMT); importantly, this state is partly reversible and may be amenable to intervention to slow disease progression. As lesions advance, epithelial cells more fully undergo EMT, acquiring greater motility, invasiveness, and metastatic capability, which increases susceptibility to malignant conversion. MicroRNAs (miRNAs) are key molecular regulators in the transition from chronic gastritis to GC through EMT modulation. This review comprehensively discusses inflammation-driven EMT activation and functionally classifies pro-EMT oncomiRNAs (e.g., miR-21, miR-155) and anti-EMT tumor-suppressive miRNAs (e.g., miR-200 family, let-7 family, miR-34a), delineating a complex crosstalk network among inflammation, miRNA, and EMT. We further evaluate miRNAs as non-invasive biomarkers for early detection and prognosis of GPL and discuss emerging therapeutic strategies targeting the miRNA–EMT axis, including nanoparticle- or exosome-based delivery systems, miRNA antagonists, and miRNA sponges. Nevertheless, clinical application of circulating miRNAs remains limited by insufficient assay standardization and validation, incomplete target specificity, off-target effects, suboptimal delivery efficiency, and a lack of large-scale clinical evidence. By integrating molecular mechanisms and transformation status of miRNA-EMT axis in GPL, this review provides new insights for precision prevention and targeted intervention in gastric carcinogenesis.


  • Open Access

    Collagenous gastritis: current understanding of a rare immune-mediated gastropathy across pediatric and adult phenotypes—from pathogenesis to therapeutic strategies

    by Tai Zhang, Ting Chen, Beihua Zhang, Xudong Tang

    Collagenous gastritis (CG) is a rare chronic inflammatory disorder defined histologically by a subepithelial collagen band exceeding 10 μm, together with a chronic inflammatory infiltrate within the lamina propria. First described in 1989, CG presents with a striking age-stratified dichotomy. The pediatric phenotype is dominated by treatment-refractory iron-deficiency anemia and chronic abdominal pain, with disease usually confined to the stomach. The adult phenotype is dominated by chronic watery diarrhea and frequently coexists with collagenous colitis as part of a broader collagenous gastroenteropathy spectrum. The pathogenesis is widely held to be immune-mediated. Strong associations exist with autoimmune conditions, including celiac disease, common variable immunodeficiency (CVID), and systemic lupus erythematosus (SLE). Recent gene-expression and single-cell studies have identified mixed T-helper 1 (Th1) and T-helper 2 (Th2) cytokine profiles in gastric tissue, together with α4β7-mediated mucosal homing of activated CD4 + T cells, suggesting complex immune dysregulation rather than a primary disorder of collagen biosynthesis. Implicated triggers include certain medications—notably olmesartan—and, more speculatively, infectious agents; a single case report has increased the possibility of Epstein–Barr virus (EBV) reactivation. A single proteomics study has identified reduced epidermal growth factor (EGF) expression as a candidate biomarker, suggesting impaired mucosal repair, although further validation is needed. Diagnosis demands a high index of clinical suspicion and rests on histopathological examination of multi-site gastric biopsies since endoscopic appearances range from normal mucosa to characteristic nodular patterns. Management is empirical and individualized: symptomatic support with proton pump inhibitors (PPIs) and iron supplementation, anti-inflammatory therapy with topically targeted budesonide, dietary intervention in selected patients, and emerging mechanism-targeted approaches including α4β7 blockade. This narrative review synthesizes 101 articles published between 1989 and 31 August 2025, describing approximately 730 histopathologically confirmed CG cases (≈40% pediatric, ≈60% adult; overall female-to-male ratio ≈2.1:1). Replicated findings are distinguished throughout from those based on single reports, with preliminary observations explicitly flagged as hypothesis-generating.


  • Open Access

    Modified gegen qinlian decoction ameliorates Veillonella parvula-exacerbated ulcerative colitis via restoration of intestinal mucosal barrier function

    by Meiling She, Xinyi Dai, Xintong Wang, Zheng Wang, Jiaqi Zhang, Zhuo Shi, Ying Peng, Xiaobo Li, Ting Chen, Xudong Tang

    Introduction: Ulcerative colitis (UC) is being increasingly connected to the pathogen Veillonella parvula (V. parvula). Modified Gegen Qinlian Decoction (MGQD), a traditional Chinese medicine therapy, is used to treat UC. However, the underlying mechanism by which V. parvula exacerbates UC and whether MGQD can alleviate it is unknown. Methods: MGQD therapy was tested on pathogen-free and pseudo-germ-free mice infected with V. parvula. Colitis severity was determined by disease activity index, colon length, and histology. Transmission electron microscopy, Western blot, immunofluorescence, and immunohistochemistry were used to assess the integrity of the intestinal mucosal barrier. In vitro , mouse colonic organoids were utilized to examine the effects of baicalin and puerarin on inflammation-induced downregulation of Muc2 and ZO-1. Results: MGQD therapy dramatically reduced the severity of colitis in both mouse models. MGQD restored the integrity of the mucus and mechanical barriers. Furthermore, baicalin and puerarin reduced inflammation-induced downregulation of Muc2 and ZO-1 in mouse colonic organoids. Discussion: These findings demonstrate that MGQD alleviates intestinal barrier dysfunction caused by V. parvula, providing novel mechanistic insight for the management of chronic colitis.

  • Open Access

    Global research trends in non-coding RNA and intestinal epithelial homeostasis: an integrated bibliometric analysis (2007–2024)

    by Xinxin Wang, Xuan Li, Yongtian Wen, Bochao Yuan, Xudong Tang, Ting Chen

    Background: Non-coding RNAs regulate gene expression through various mechanisms, playing key roles in life activities. Intestinal epithelial homeostasis (IEH) is a dynamic equilibrium state formed by the interaction of intestinal mucosal barrier, intestinal environment and other factors. There are many recorded documents demonstrating a close relationship between non-coding RNAs and IEH. Therefore, it is significant to retrospectively explore the current status, hotspots and trends of non-coding RNA (ncRNA) and IEH through a bibliometric perspective. Methods: We searched the Web of Science (WOS) for studies related to non-coding RNA and intestinal epithelial homeostasis from 1980 to December 2024, then downloaded the data. CiteSpace 6.3.1, VOSviewer 1.6.20, SCImago Graphica and Excel software were used to draw knowledge visualization maps. Results: A total of 667 publications relevant to ncRNA and IEH were included. The publication output and citation counts generally demonstrated an initial increase followed by a subsequent decrease. The publications have received a total of 18,979 citations, with an average of approximately 28 citations per article. China published the most articles, followed by the United States. Keyword analysis indicated that inflammatory bowel disease (IBD), intestinal immunity, and gut microbiota were of high importance. IBD dominates IEH research, yet circRNA is an emerging focus. Exploring ncRNAs in intestinal stem cell and colitis-associated cancer holds great research potential in the future. Multidisciplinary integration is the research trend. Conclusions: Our findings provide a comprehensive knowledge framework for researchers and clinicians aiming to explore ncRNA-based diagnostic and therapeutic strategies for IEH. Our results highlight the need for translational research to validate ncRNA-based diagnostic and therapeutic strategies for gut barrier disorders.

  • Open Access

    Ginseng and health outcomes: an umbrella review

    by Zhongyu Li, Yang Wang, Qing Xu, Jinxin Ma, Xuan Li, Yibing Tian, Yandong Wen, Ting Chen

    Background: Ginseng consumption has been associated with various health outcomes. However, there are no review articles summarizing these reports.Methods: PubMed, Embase, the Cochrane Library of Systematic Reviews, Scopus, CNKI and Wanfang databases were searched from inception to 31 July 2022. The Assessment of Multiple Systematic Reviews-2 (AMSTAR-2) and Grading of Recommendations Assessment, Development and Evaluation (GRADE) systems were used to assess the methodological quality and quality of evidence in each meta-analysis, and the results were summarized in a narrative form.Results: Nineteen meta-analyses that met the eligibility criteria were identified from among 1,233 papers. The overall methodological quality was relatively poor, with only five studies being low-quality, and 14 critically low-quality. When compared with control treatments (mainly placebo), ginseng was beneficial for improving fatigue and physical function, sexual function, menopausal symptoms, metabolic indicators, inflammatory markers, unstable angina and respiratory diseases. Adverse events included gastrointestinal symptoms and potential bleeding; however, no serious adverse events were reported.Conclusion: This umbrella review suggests that ginseng intake has beneficial therapeutic effects for diverse diseases. However, the methodological quality of studies needs to be improved considerably. In addition, it is imperative to establish the clinical efficacy of ginseng through high-quality randomized controlled trials.


  • Open Access

    Nigella sativa and health outcomes: An overview of systematic reviews and meta-analyses

    by Zhongyu Li, Yang Wang, Qing Xu, Jinxin Ma, Xuan Li, Jiaxing Yan, Yibing Tian, Yandong Wen, Ting Chen

    Background: Nigella sativa (N. sativa) consumption has been associated with various health outcomes; however, the results are not completely consistent.Objectives: This overview of systematic reviews and meta-analyses aimed to evaluate the reporting and methodological quality, and to grade the available evidence of associations between N. sativa and health outcomes.Methods: PubMed, Cochrane Library, Embase, and Scopus databases were searched from their inception to September 30, 2022. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2009 statement, Assessment of Multiple Systematic Reviews (AMSTAR) 2 checklist, and Grades of Recommendations, Assessment, Development and Evaluations (GRADE) systems were used to assess the reporting, methodological, and evidence quality for each meta-analysis, respectively. The results were synthesized in a narrative form.Results: This overview included 20 eligible meta-analyses published in peer-reviewed journals between 2013 and 2021. The overall methodological quality was relatively poor, with only one moderate quality, four low quality, and 15 critically low quality studies. For reporting quality, items two, five, eight, nine, 15, and 24 need to improve. Among the 110 outcome indicators of the quality of evidence, five were graded as moderate, 17 as low, and 88 as very low. Risk of bias, inconsistency, and imprecision were the main downgrading factors.Conclusion: This overview suggests that N. sativa is beneficial for various clinical outcomes. However, there are certain limitations to reporting and methodological quality. The clinical efficacy of N. sativa requires confirmation in high-quality, large-sample, randomized controlled trials.


  • Open Access

    Traditional Chinese medicine based on Tongjiang methodology combined with proton pump inhibitor (PPI) step-down in treating non-erosive reflux disease: a study protocol for a multicentered, randomized controlled clinical trial

    by Xia Li, Haomeng Wu, Beihua Zhang, Ting Chen, Xiaoshuang Shi, Jinxin Ma, Jiaqi Zhang, Xudong Tang, Fengyun Wang

    Background: Non-erosive reflux disease (NERD) is characterized by typical gastroesophageal reflux symptoms, such as heartburn and regurgitation but an absence of esophageal mucosal damage during upper gastrointestinal endoscopy. Although proton pump inhibitors (PPIs) are the first line therapy, almost 50% of patients with NERD fail to respond to this treatment. Traditional Chinese medicine (TCM) can better relieve the symptoms of NERD. Therefore, a randomized controlled trial (RCT) was designed to investigate the efficiency of TCM granules based on Tongjiang (TJ) methodology combined with PPI step-down therapy for NERD patients who did not respond to PPIs alone. Method: This multicentered, double-blinded, RCT with two parallel groups will recruit 174 participants who will be randomized into the TCM granules combined with PPI step-down group (n = 87) and the TCM granules placebo combined with PPI step-down group (n = 87). Both groups of participants will receive 6 weeks of treatment and 4 weeks of follow-up, and all participants will be assessed for related symptoms, mental health status, and quality of life at each visit. The primary outcome measurements include visual analog scale (VAS) for heartburn and regurgitation and the major symptoms scale. The secondary outcome measurements include PPI withdrawal rate, symptom recurrence rate, minor symptoms scale, SF-36, PRO, SAS, SDS, GERD–HRQL, and TCM syndromes scales. Discussion: Previous research has shown that TCM is capable to alleviate NERD symptoms. This trial will help to provide a better understanding of the synergistic efficiency of the combination of TCM and PPIs, to explore whether the dosage of PPIs can be reduced after the supplement of TCM granules and to provide a feasible plan to reduce dependencies or withdraw NERD patients from PPIs. The outcome of this trial is expected to reduce the symptom recurrence rates, lessen patients’ physical and psychological burdens, and achieve good social benefits. Trial registration: Clinicaltrials.gov NCT04340297. Registered on April 9, 2020